The Life Science Innovator
A WBBA Publication
WBBA Industry Working Groups
Connect with your peers to meet the unique challenges your Organization faces.
(Open to ALL WBBA Members)
The goal of this group is to give people who are responsible for “getting the word out” for their respective organizations a closed-forum to discuss the unique issues, problems and challenges that face the people charged with fulfilling the role of communications, public relations, marketing, community outreach and investor relations, whether by specific title or by having it as one of their responsibilities. Join the group!
(Open to WBBA Core & Institution Member HR professionals)
You are invited to join over 60 of your HR colleagues from WBBA member companies, as we network, share ideas and exchange information about the challenges and issues we encounter while working in the biotechnology and biomedical fields. The Human Resources Group offers a variety of ways to connect with your colleagues. This is an excellent way to learn up-to-date information from professionals within our industry. You do not need to have an HR title in order to attend these meetings; you simply need to perform the human resources function for your company. Join the group!
Clean Science Group
(Open to any WBBA member interested in clean science and sustainability)
The goal of the WBBA Clean Science Group is to have a variety of representatives of the region's life science community dialoguing about solutions to minimize the impact of our scientific pursuits on the region. We also want to educate each other on the systems that are currently available to reduce, reuse, and recycle, and the associated costs of such systems. Are you interested in dialoguing about creating clean science? If so, then join the WBBA Clean Science Group on LinkedIn. We would like to have participation from various groups in the lab including facilities, operations, and lab managers. Join the group!
Supply Chain Group
(Open to WBBA Core & Institution Member Supply Chain/Purchasing professionals)
This group offers supply chain, purchasing, and sourcing professionals an opportunity to network and discuss the challenges they face and share best practices. If interested, please contact Blythe Price at email@example.com. Join the group!
(Open to WBBA Core & Institution Member Facilities/Engineering professionals)
This group offers Facilities and Engineering professionals an opportunity to network and discuss the challenges they face and share best practices. If interested, please contact Blythe Price at firstname.lastname@example.org. Join the group!
Return to top
Valuation of Your Early Drug Candidate
By Linda M. Pullan, PhD, writing on behalf of ShareVault
ShareVault has recently published a white paper titled “Valuation of Your Early Drug Candidate”, another in a series of ShareVault whitepapers that capture Linda Pullan’s knowledge and expertise in biopharma partnering.
Here’s an excerpt (the full whitepaper can be downloaded below):
“The complexity of valuing a drug candidate for a partnering deal varies. Drug candidates that have completed a Phase II program have more defined product profiles and can be valued using, in part, market research and physician interviews. Early drug candidates, due to numerous factors such as long development timelines before the value is realized, many questions yet unanswered, ever-changing market conditions and regulatory requirements, and the high risk of technical failure can be more difficult to value. Valuation methods exist, but all are imperfect, and at the end of the day the value of your project will ultimately be what someone is willing to pay for it. And, just like that piece of art, what a partner is willing to pay will most likely be based on how well they understand the opportunity, how well it fits in with their portfolio of drugs and strategy, and how much competition there is for it. But they, like you, will use some of these basic valuation methods to shape their thinking about the value.”
Return to newsletter main page